Genomics & Precision Medicine Penny Stocks

US-listed genomics and precision-medicine penny stocks priced $0.50 to $5, ranked by today's percentage change. Gene editing, gene therapy, sequencing technology, liquid biopsy, companion diagnostics, and precision-medicine platforms. Updated intraday.

Data as of 8/29/2026 2:11:53 AM · Intraday prices · 55 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1RCKTRocket Pharmaceuticals, Inc. Common StockHealthcare$3.8350+6.49%1.3M
2PASGPassage Bio, Inc. Common StockHealthcare$4.4750+4.39%8K
3ALLRAllarity Therapeutics, Inc. Common StockHealthcare$1.4100+2.90%128K
4VYGRVoyager Therapeutics, Inc. Common StockHealthcare$3.5350+2.17%168K
5LNAILunai Bioworks Inc. Common StockHealthcare$2.3450+2.13%35K
6INOInovio Pharmaceuticals, Inc.Healthcare$1.2850+1.59%649K
7CTKBCytek Biosciences, Inc. Common StockHealthcare$4.6800+1.41%710K
8PHIOPhio Pharmaceuticals Corp. Common StockHealthcare$1.1300+0.45%17K
9TCRXTScan Therapeutics, Inc. Common StockHealthcare$0.7710+0.37%149K
10CAMPCAMP4 Therapeutics Corporation Common StockHealthcare$4.1450+0.36%43K
11MDXHMDxHealth SA Ordinary SharesHealthcare$0.7050+0.21%268K
12QTRXQuanterix Corporation Common StockHealthcare$2.62700.00%297K
13GNPXGenprex, Inc. Common StockHealthcare$3.64100.00%52K
14SERASera Prognostics, Inc. Class A Common StockHealthcare$2.04200.00%22K
15BGLCBioNexus Gene Lab Corp Common stockHealthcare$1.55400.00%3K
16TNYATenaya Therapeutics, Inc. Common StockHealthcare$0.6930-0.60%226K
17PRMEPrime Medicine, Inc. Common StockHealthcare$3.6000-0.69%2.5M
18CSBRChampions Oncology, Inc.Healthcare$4.9500-0.70%3K
19MGXMetagenomi Therapeutics, Inc. Common StockHealthcare$1.1950-0.83%76K
20BCDABioCardia, Inc. Common StockHealthcare$1.1550-0.85%159K
21CBUSCibus, Inc. Class A Common StockHealthcare$1.6500-0.90%27K
22SEERSeer, Inc. Class A Common StockHealthcare$1.9960-1.00%50K
23IMNNImunon, Inc. Common StockHealthcare$1.6000-1.25%31K
24MYGNMyriad Genetics IncHealthcare$3.1450-1.26%537K
25OPKOpko Health Inc.Healthcare$1.4850-1.33%2.2M
26ACIUAC Immune SAHealthcare$2.6400-1.48%102K
27PRQRProQR Therapeutics N.V. Ordinary SharesHealthcare$2.2850-1.51%129K
28CDIOCardio Diagnostics Holdings Inc. Common stockHealthcare$1.8500-1.60%14K
29BNGOBionano Genomics, Inc. Common StockHealthcare$1.1650-1.65%45K
30MBIOMustang Bio, Inc.Healthcare$0.5360-2.29%9K
31NAUTNautilus Biotechnolgy, Inc. Common StockHealthcare$0.8950-2.36%469K
32CRBUCaribou Biosciences, Inc. Common StockHealthcare$1.6400-2.41%227K
33QSIQuantum-Si Incorporated Class A Common StockHealthcare$0.7830-2.43%2.3M
34LABStandard BioTools Inc. Common StockHealthcare$0.6560-2.43%375K
35LXEOLexeo Therapeutics, Inc. Common StockHealthcare$4.6900-2.51%233K
36QUCYQuantum Cyber N.V. Ordinary SharesHealthcare$1.4250-2.72%150K
37IBIOiBio, Inc. Common StockHealthcare$1.3950-2.86%505K
38JSPRJasper Therapeutics, Inc. Common StockHealthcare$0.7130-3.00%261K
39IMDXInsight Molecular Diagnostics Inc. Common StockHealthcare$4.1400-3.03%39K
40OABIOmniAb, Inc. Common StockHealthcare$4.5020-3.04%1.1M
41OCGNOcugen, Inc. Common StockHealthcare$1.3380-3.65%1.2M
42ALLOAllogene Therapeutics, Inc. Common StockHealthcare$2.0220-3.83%1.1M
43IRDOpus Genetics, Inc. Common StockHealthcare$3.8400-3.90%791K
44SANASana Biotechnology, Inc. Common StockHealthcare$3.9280-3.91%856K
45ACRVAcrivon Therapeutics, Inc. Common StockHealthcare$2.1050-4.19%41K
46ENGNenGene Therapeutics Inc. Common StockHealthcare$1.8770-4.19%195K
47EDITEditas Medicine, Inc. Common StockHealthcare$3.1200-4.55%3.1M
48MXCTMaxCyte, Inc. Common StockHealthcare$1.2450-4.69%187K
49AVXLAnavex Life SciencesHealthcare$3.0500-4.79%779K
50XCURExicure, Inc. Common StockHealthcare$1.2850-5.32%3K

How Genomics Penny Stocks Trade

Genomics at sub-$5 is a mix of gene-editing platforms (CRISPR, base/prime editing, ZFNs), gene therapy specialists, sequencing-tool makers, and diagnostics companies. Like oncology, the trading is catalyst-driven — clinical readouts, FDA actions, and competitive technology announcements move individual names sharply.

  • Editing technology approach: CRISPR-Cas9, base editing, prime editing, and ZFN platforms have different IP, safety profiles, and timelines. Don't aggregate.
  • Gene therapy reimbursement: approved gene therapies cost $1M-$3M per patient. Payer adoption shapes commercial trajectory.
  • Sequencing instrument cycles: sequencing-tool plays trade with the Illumina/Element/etc. competitive landscape.
  • FDA novel-modality posture: the agency's evolving framework for gene/cell therapies affects approval timelines.
  • IP litigation: the CRISPR patent landscape has had years of litigation. Court rulings move names that depend on specific IP positions.
  • Manufacturing scale: gene therapies require specialized manufacturing. Companies with internal capacity trade at premiums to outsourced models.
  • Rare disease focus: orphan indications get faster approvals and pricing power but smaller markets. Trade-offs to weigh.
  • Dilution profile: like other clinical-stage biotechs, sub-$5 genomics names raise capital frequently — see our dilution explainer.

See also: biotech penny stocks (broader), oncology penny stocks, penny stocks under $1.